Santrone Uses, Dosage, Side Effects and more
An anthracenedione-derived antineoplastic agent.
Santrone has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2.
| Trade Name | Santrone |
| Availability | Prescription only |
| Generic | Mitoxantrone |
| Mitoxantrone Other Names | Mitoxantrona, Mitoxantrone, Mitoxantronum |
| Related Drugs | Gilenya, Tysabri, Vumerity, methotrexate, estradiol, Premarin, rituximab, Rituxan, cyclophosphamide, Xtandi |
| Type | |
| Formula | C22H28N4O6 |
| Weight | Average: 444.4809 Monoisotopic: 444.200884648 |
| Protein binding | 78% |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | Hong Kong |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Santrone is a chemotherapeutic agent used for the treatment of secondary progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis.
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
Santrone is also used to associated treatment for these conditions: Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia (APL), Lymphoma, Hodgkins, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma, Allogeneic peripheral haematopoietic stem cell transplant
How Santrone works
Santrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Santrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. It has a cytocidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity.
Toxicity
Severe leukopenia with infection.
Food Interaction
No interactions found.Santrone Drug Interaction
Moderate: diltiazem, diltiazemUnknown: sulfamethoxazole / trimethoprim, sulfamethoxazole / trimethoprim, pancrelipase, pancrelipase, meperidine, meperidine, glucose, glucose, lithium, lithium, pregabalin, pregabalin, metoprolol, metoprolol, metoprolol, metoprolol, acetaminophen, acetaminophen
Santrone Disease Interaction
Major: infections, heart disease, liver disease, myelosuppressionModerate: hyperuricemia
Volume of Distribution
- 1000 L/m2
Elimination Route
Poorly absorbed following oral administration
Half Life
75 hours
Clearance
- 21.3 L/hr/m2 [Elderly patients with breast cancer receiving IV administration of 15-90 mg/m2]
- 28.3 L/hr/m2 [Non-elderly patients with nasopharyngeal carcinoma receiving IV administration of 15-90 mg/m2]
- 16.2 L/hr/m2 [Non-elderly patients with malignant lymphoma receiving IV administration of 15-90 mg/m2]
